Sistema endocanabinoide y desarrollo de esteatosis hepática

The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SE...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Valenzuela,Carina, Castillo,Valeska, Ronco,Ana María, Aguirre,Carolina, Hirsch,Sandra, Llanos,Miguel
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2014
Materias:	Endocannabinoids Liver Diseases Receptors Cannabinoid
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000300010
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872014000300010
record_format	dspace
spelling	oai:scielo:S0034-988720140003000102014-09-02Sistema endocanabinoide y desarrollo de esteatosis hepáticaValenzuela,CarinaCastillo,ValeskaRonco,Ana MaríaAguirre,CarolinaHirsch,SandraLlanos,Miguel Endocannabinoids Liver Diseases Receptors Cannabinoid The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SEC originates metabolic alterations in several tissues, resulting in the typical manifestations of the metabolic syndrome. Liver steatosis of different origins constitutes a physiopathological condition where an altered hepatic SEC is observed. In this condition, there is an increased expression of RCB1 and/or higher endocannabinoid levels in different hepatic cells, which may exert an autocrine/paracrine hyperstimulation of RCB1/RCB2. Activation of RCB1 stimulate the expression of several hepatocyte lipogenic factors, thus leading to increased de novo fatty acids synthesis and consequently to an abnormal accumulation of triglycerides. The effect of RCB2 activity on hepatic function is still controversial because, on one side its stimulation has an interesting protective effect on alcoholic liver disease while, on the other, it may enhance the development of hepatic steatosis in experimental models of diet-induced obesity. In this review we discuss the proposed mechanisms by which SEC is involved in the etiology of hepatic steatosis, as well as the therapeutic possibilities involving peripheral RCB1/RCB2 antagonism/agonism, for the treatment of this condition.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.3 20142014-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000300010es10.4067/S0034-98872014000300010
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Endocannabinoids Liver Diseases Receptors Cannabinoid
spellingShingle	Endocannabinoids Liver Diseases Receptors Cannabinoid Valenzuela,Carina Castillo,Valeska Ronco,Ana María Aguirre,Carolina Hirsch,Sandra Llanos,Miguel Sistema endocanabinoide y desarrollo de esteatosis hepática
description	The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SEC originates metabolic alterations in several tissues, resulting in the typical manifestations of the metabolic syndrome. Liver steatosis of different origins constitutes a physiopathological condition where an altered hepatic SEC is observed. In this condition, there is an increased expression of RCB1 and/or higher endocannabinoid levels in different hepatic cells, which may exert an autocrine/paracrine hyperstimulation of RCB1/RCB2. Activation of RCB1 stimulate the expression of several hepatocyte lipogenic factors, thus leading to increased de novo fatty acids synthesis and consequently to an abnormal accumulation of triglycerides. The effect of RCB2 activity on hepatic function is still controversial because, on one side its stimulation has an interesting protective effect on alcoholic liver disease while, on the other, it may enhance the development of hepatic steatosis in experimental models of diet-induced obesity. In this review we discuss the proposed mechanisms by which SEC is involved in the etiology of hepatic steatosis, as well as the therapeutic possibilities involving peripheral RCB1/RCB2 antagonism/agonism, for the treatment of this condition.
author	Valenzuela,Carina Castillo,Valeska Ronco,Ana María Aguirre,Carolina Hirsch,Sandra Llanos,Miguel
author_facet	Valenzuela,Carina Castillo,Valeska Ronco,Ana María Aguirre,Carolina Hirsch,Sandra Llanos,Miguel
author_sort	Valenzuela,Carina
title	Sistema endocanabinoide y desarrollo de esteatosis hepática
title_short	Sistema endocanabinoide y desarrollo de esteatosis hepática
title_full	Sistema endocanabinoide y desarrollo de esteatosis hepática
title_fullStr	Sistema endocanabinoide y desarrollo de esteatosis hepática
title_full_unstemmed	Sistema endocanabinoide y desarrollo de esteatosis hepática
title_sort	sistema endocanabinoide y desarrollo de esteatosis hepática
publisher	Sociedad Médica de Santiago
publishDate	2014
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000300010
work_keys_str_mv	AT valenzuelacarina sistemaendocanabinoideydesarrollodeesteatosishepatica AT castillovaleska sistemaendocanabinoideydesarrollodeesteatosishepatica AT roncoanamaria sistemaendocanabinoideydesarrollodeesteatosishepatica AT aguirrecarolina sistemaendocanabinoideydesarrollodeesteatosishepatica AT hirschsandra sistemaendocanabinoideydesarrollodeesteatosishepatica AT llanosmiguel sistemaendocanabinoideydesarrollodeesteatosishepatica
_version_	1718436744026652672

Sistema endocanabinoide y desarrollo de esteatosis hepática

Ejemplares similares